TRDA Insider Trading
Insider Ownership Percentage: 7.59%
Insider Buying (Last 12 Months): $31,955.04
Insider Selling (Last 12 Months): $1,294,741.67
Entrada Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Entrada Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Entrada Therapeutics Share Price & Price History
Current Price: $8.13
Price Change: ▲ Price Increase of +0.27 (3.44%)
As of 04/17/2025 05:00 PM ET
Entrada Therapeutics Insider Trading History
Entrada Therapeutics Institutional Trading History
Data available starting January 2016
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Read More on Entrada Therapeutics
Volume
158,883 shs
Average Volume
124,051 shs
Market Capitalization
$305.65 million
P/E Ratio
5.11
Dividend Yield
N/A
Beta
0.04
Who are the company insiders with the largest holdings of Entrada Therapeutics?
Who are the major institutional investors of Entrada Therapeutics?
Which institutional investors are buying Entrada Therapeutics stock?
In the previous quarter, TRDA stock was purchased by institutional investors including:
- Harbor Capital Advisors Inc.